Explore innovative treatment strategies for elderly patients with acute myeloid leukemia who can't handle intensive therapy. Learn about assessing fitness for treatment and the significance of genetic mutations. Discover how modern therapies like azacitidine and venetoclax are reshaping care for frail patients. Key clinical trials, including Viali-A and LACEWING, reveal improved outcomes. The episode delivers valuable insights into navigating the complexities of AML management in older, less fit patients.

Dr. Amar Kelkar, a hematology and oncology expert from Dana-Farber Cancer Institute, delves into allogeneic transplant options for acute myeloid leukemia (AML). He discusses the various conditioning regimens and how to choose the best one for patients. The conversation also highlights the critical role of measurable residual disease testing and maintenance therapies. Kelkar sheds light on graft-versus-host disease and recent advancements in haploidentical transplants, addressing racial disparities in transplant outcomes for better equity.

Dr. Amar Kelkar, an instructor at Harvard Medical School and specialist at Dana-Farber, joins for an enlightening dive into allogeneic transplants for AML. He unpacks key eligibility criteria for patients, stressing the importance of minimal residual disease status. The conversation also illuminates the critical role of HLA matching and donor selection factors. Additionally, Dr. Kelkar compares various stem cell sources, revealing unique insights about outcomes in haploidentical and cord blood transplants. His expert perspective makes this complex topic accessible.

This discussion highlights cutting-edge maintenance therapies for acute myeloid leukemia (AML). It reviews the role of cytarabine consolidation and the significance of hypomethylating agents in restoring gene function. Personal anecdotes enrich insights on the treatment journey of patients. Challenges surrounding targeted therapies, especially FLT3 inhibitors, are explored alongside the promising drug giltaritinib. The importance of evaluating clinical trial data to enhance patient outcomes is emphasized, making for a comprehensive overview of AML therapies.

This week, we continue our discussion on consolidation and maintenance therapies for AML, this time highlighting the role of allogeneic stem cell transplants. This episode builds on our prior episode, so if you have not listened to this just yet, we highly recommend doing so! Episode contents: - A recap on approach to AML consolidation - The role of allogeneic transplants - The role of MRD testing in AML management****Have some time and want to make some extra money? Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Dive into the fascinating world of Acute Myeloid Leukemia treatment! Discover the essential phases of consolidation and maintenance therapy to prevent relapse. The discussion highlights genetic abnormalities and their impact on patient care, including who qualifies for allogeneic transplants. Get insights on the latest advancements in consolidation strategies, especially the effectiveness of high-dose cytarabine. Personal stories and lighthearted moments make complex topics engaging!

This week, we round out our discussion regarding AML induction, this time focusing on the treatment options in the first line setting. We go through the various options, the dosing strategies, and the data behind them. Be sure to check out parts one and two of this three-part induction discussion, as we continue to build on these concepts! Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation!Episode contents: - What are our options for upfront induction therapy?- How do we select patients for the "add-ons" to induction therapy?- What is the data behind these options? ****This episode is sponsored by our Global Research Partners! Have some time and want to make some extra money? Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this week’s episode, we continue onto part two of our three-part discussion on AML induction, this week focusing on selecting our up-front regimen. Be sure to check out last week’s episode, as this one builds on that one. Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation!Episode contents: - What is "7+3"? - How do we pick our approach to management?- Do we ever add anything else to our induction back bone? ****Have some time and want to make some extra money? Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Dive into the intricacies of Acute Myeloid Leukemia treatment, starting with essential definitions and an overview. Learn the vital role of leukapheresis and cytoreduction when faced with high blast levels. Explore the importance of molecular testing for effective risk stratification and treatment planning. Discover the phases of AML treatment, emphasizing morphologic remission and response criteria. Tune in for a blend of clinical insights and engaging anecdotes that illuminate this complex topic.

Explore the intricacies of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) diagnosis. Discover how bone marrow biopsy reports play a crucial role in identifying these conditions. Learn about the WHO and ICC classifications and disease-defining cytogenetic markers. Delve into a clinical case highlighting macrocytic anemia and thrombocytopenia. Unpack the challenges of interpreting pathology reports and the importance of collaborative discussions for accurate diagnoses. Stay updated on the latest diagnostic techniques and genetic implications for effective treatment.